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Abstract
Metastatic colorectal cancer remains a serious health concern with poor patient survival. Although 5-Fluorouracil (5-
FU) or 5-FU plus oxaliplatin (FOLFOX) is the standard therapy for colorectal cancer, it has met with limited success.
Recurrence of the tumor after chemotherapy could partly be explained by the enrichment of the chemo-resistant
sub-population of cancer stem cells (CSCs) that possess the ability for self-renewal and differentiation into different
lineages in the tumor. Therefore development of therapeutic strategies that target CSCs for successful treatment of
this malignancy is warranted. The current investigation was undertaken to examine the effectiveness of the
combination therapy of dasatinib (a Src inhibitor) and curcumin (a dietary agent with pleiotropic effect) in
inhibiting the growth and other properties of carcinogenesis of chemo-resistant colon cancer cells that are
enriched in CSCs sub-population. Remnants of spontaneous adenomas from APC
Min +/- mice treated with dasatinib
and/or curcumin were analyzed for several cancer stem cell markers (ALDH, CD44, CD133 and CD166). Human
colon cancer cells HCT-116 (p53 wild type; K-ras mutant) and HT-29 (p53 mutant; K-ras wild type) were used to
generate FOLFOX resistant (referred to as CR) cells. The effectiveness of the combination therapy in inhibiting
growth, invasive potential and stemness was examined in colon cancer CR cells. The residual tumors from APC
Min
+/- mice treated with dasatinib and/or curcumin showed 80-90% decrease in the expression of the CSC markers
ALDH, CD44, CD133, CD166. The colon cancer CR cells showed a higher expression of CSCs markers, cell invasion
potential and ability to form colonospheres, compared to the corresponding parental cells. The combination
therapy of dasatinib and curcumin demonstrated synergistic interactions in CR HCT-116 and CR HT-29 cells, as
determined by Calcusyn analysis. The combinatorial therapy inhibited cellular growth, invasion and colonosphere
formation and also reduced CSC population as evidenced by the decreased expression of CSC specific markers:
CD133, CD44, CD166 and ALDH. Our data suggest that the combination therapy of dasatinib and curcumin may
be a therapeutic strategy for re-emergence of chemo-resistant colon cancer by targeting CSC sub-population.
Background
Colorectal cancer, the third most common cancer affect-
ing men and women equally [1], remains a huge health
concern. It is the second most common cause of can-
cer-related deaths in the United States and other devel-
oped countries. Although with early detection and
surgical resection, the 5-year survival rate can reach
90%, nearly 50% of patients with colorectal carcinoma
develop recurrent disease [2,3]. Most of the colon can-
cer deaths results from the metastatic spread of che-
motherapy-resistant cells to the liver and other organs
[4] and thus, metastasis remains a poor prognostic indi-
cator [5].
Over the last decade, there has been a growing body
of evidence that support the concept of cancer stem cell
(CSC) model as an explanation for the initiation, pro-
gression and recurrence of cancer. Epithelial cancers
including colorectal cancer are now believed to be dis-
eases driven by a minor subpopulation of self renewing
cancer stem cells (CSCs). CSCs also have the potential
to invade and form distant metastasis [6-10]. Biologically
distinct and relatively rare populations of tumor-initiat-
ing cells or CSCs have been detected by several methods
and markers established in a variety of cancers, includ-
ing the colon [11-13]. Furthermore, CSCs are known to
show resistance to a numbero fc o n v e n t i o n a lc h e -
motherapies and thus play a significant role in
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treatment regimen target the non-CSCs population of
the tumor and fail to eliminate the CSCs [8,14]. The
remaining chemotherapy-resistant CSCs lead to che-
motherapy-refractory tumor, and may explain the diffi-
culty in complete eradication of cancer and/or
recurrence. Therefore, development of therapeutic stra-
tegies that specifically target CSCs is warranted in redu-
cing the risk of relapse and metastasis.
5-Fluorouracil (5-FU) or 5-FU plus oxaliplatin (FOL-
FOX) remains the mainstay of colorectal cancer che-
motherapeutics. Although these chemotherapeutic
regimens produce a response in majority of the cases,
virtually all the responses are incomplete and emergence
of resistance with recurrence of the cancer is universal.
There is also a cost of additional toxicities, some of
which are even fatal. Therefore, validation of a non-
toxic agent that could improve upon the current che-
motherapeutic regimen(s) would be highly desirable. In
an attempt to develop an effective treatment strategy, a
combination therapeutic regimen comprising of dasati-
nib and curcumin (diferuloylmethane), was therefore
tested for its efficacy in inhibiting growth and eliminat-
ing the CSCs in chemo-resistant colon cancer cells.
Dasatinib is a highly potent inhibitor of Src kinases
and Abl kinases [15,16] and is currently employed for
imatinib resistant CML and (Ph+) ALL treatment
[15,16]. In addition to hematological malignancies, dasa-
tinib has been shown to be effective in solid tumors and
demonstrate multiple effects like inhibition of cellular
growth, migration and invasion [15-17]. Our recent stu-
dies demonstrate that dasatinib regulates growth of
breast cancer cells by modulating EGFR signaling [18].
Also, since multiple signaling pathways are deregulated
in carcinogenesis, several therapeutic regimens that tar-
get multiple signaling are being investigated and devel-
oped. In this context, we have recently shown that
dasatinib act synergistically with the pan-erbB inhibitor
EBIP (ErbB inhibitory protein) as well as with curcumin
in inhibiting several processes of carcinogenesis in
breast and colon cancers [18,19]. The combination
therapies were found to be highly effective in inhibiting
cellular growth, colony formation, extracellular matrix
invasion and attenuation of various signaling pathways
[18,19].
Curcumin, the major active ingredient of turmeric, has
been shown to inhibit chemically induced carcinogenesis
in the skin, forestomach and colon when administered
during initiation and/or post-initiation phases [20-23].
Development of azoxymethane-induced preneoplastic
and neoplastic lesions of the colon is also inhibited in
experimental animals fed a diet containing curcumin
[24,25]. Curcumin has been shown to suppress various
stages of colon carcinogenesis with no discernable toxi-
city [26,27] and prevent adenoma development in the
intestinal tract of Min
+/- mice, a model of human famil-
ial adenomatous polyposis [28]. Furthermore, in a Phase
I clinical trial, curcumin was shown to be effective in
inhibiting tumor growth [29].
Herein, we demonstrate that curcumin synergizes with
dasatinib to inhibit the growth of FOLFOX-resistant
colon cancer cells that are highly enriched in CSCs. The
combination therapy is also effective in inhibiting cell
invasion and colonosphere formation, the latter of
which is considered to be surrogate for tumor.
Methods and materials
Tissue procurement
Remnants of spontaneous adenomas from APC
Min +/-
mice treated with dasatinib and/or curcumin were
obtained from our previous study [30]. In this study we
have demonstrated the superior efficacy of the combina-
tion therapy in inhibiting the formation as well as indu-
cing the regression of spontaneous adenomas in APC
Min
+/- mice than either agent alone. The tissues were pro-
cessed for RNA isolation and analyzed for mRNA
expression of various CSC markers.
Cell lines and cell culture
Human colon cancer HCT-116 p53 wild type (p53 wild
type; K-ras mutant), HT-29 (K-ras wild type; p53
mutant) and their FOLFOX resistant cell lines were
used to investigate the efficacy of combined therapy of
dasatinib and curcumin. HCT-116 and HT-29 cells were
obtained from American Type Culture Collection
(ATCC, Rockville, MD). The cells were maintained in
tissue culture flasks in Dulbecco’s modified Eagle med-
ium (DMEM) in a humidified incubator at 37°C in an
atmosphere of 95% air and 5% CO2. The cell culture
medium was supplemented with 5% FBS and 1% anti-
biotic/antimycotic. FOLFOX resistant cell lines were
generated in our laboratory (as reported previously)
[31]. Briefly, HCT-116 or HT-29 cells were incubated
with a clinically relevant dose of FOLFOX (25 μM5 - F U
and 0.625 μM oxaliplatin) for one week. The adherent
cells, which survived the FOLFOX insult, were subjected
to trypsin/EDTA treatment and allowed to grow in nor-
mal DMEM for 2 weeks. The surviving cells were then
split and gradually exposed to increasing doses of FOL-
FOX to a maximal concentration of 250 μM5 - F Ua n d
6.25 μM oxaliplatin for 2-3 weeks for each treatment
period. Finally, the chemo-resistant cells were main-
tained in normal culture medium containing FOLFOX
(50 μM 5-FU + 1.25 μM oxaliplatin). The medium was
changed three times a week and the cells were passaged
using trypsin/EDTA.
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between curcumin and dasatinib
Inhibition of cell growth in response to dasatinib and or
curcumin was examined by 3-(4,5-dimethyl-thiazol-2yl)-
2,5-diphenyl-tetrazolium bromide (MTT) assay as
described previously [32]. Briefly, 5,000 cells/well were
seeded into 96-well culture plates and treated with dif-
ferent doses of dasatinib and/or curcumin for 72 h. All
CR cells were exposed to 50 μM 5-FU and 1.25 μM oxa-
liplatin with or without (control) dasatinib and/or cur-
cumin. This treatment strategy was utilized in all
subsequent experiments. The doses of dasatinib and
curcumin for combination were chosen in fixed-ratio
increments. The fraction of cells affected (Fa) by various
treatments as determined by MTT assay, was utilized to
generate dose response curves for dasatinib, curcumin
and the combination therapy by employing Calcusyn
software (Biosoft, Ferguson, MO). Further, Combination
Indices (CI) were produced by Calcusyn software that
utilizes the methodology applied by Chou and Talalay
for formal synergy analyses [33]. This method utilizes a
multiple drug-effect equation derived from enzyme
kinetics model in which the output is represented as
combination indices (CI) and/or isobologram analysis.
Calcusyn software defines synergy when CI value is < 1.
Synergy was defined based on terminology of Chou [34].
Based on CI values, the extent of synergism/antagonism
may be determined. In brief, CI values between 0.9 and
0.85 would suggest a moderate synergy, whereas those
in the range of 0.7 to 0.3 are indicative of clear synergis-
tic interactions between the drugs. On the other hand,
CI values in the range of 0.9 to 1.10 would suggest a
near additive effect. All assays were performed in
quadreplicates.
Dose Reduction Index (DRI) determination
DRI is the measure of fold-decrease of individual agent
when used in synergistic combination to achieve a given
effect level compared with the doses of each drugs
alone. The Calcusyn software was employed to calculate
the DRI for dasatinib in CR cancer cell lines. The data
generated from growth inhibition assays (Fa values for
different combination doses) was utilized to determine
DRIs.
Isolation of RNA and quantitative Polymerase Chain
Reaction (PCR) Analysis
Total RNA was extracted from parental and chemo-
resistant HCT-116 cells using Trizol reagent according
to the manufacturer’s instructions. RNA concentration
was measured spectrophotometrically at an optical den-
sity of 260 nm. Quantitative reverse transcription-poly-
merase chain reaction (RT-PCR) was performed using
the GeneAmp RNA PCR Kit (Applied Biosystems,
Foster City, CA). Briefly, 1 μg of purified RNA was
reverse-transcribed and the transcribed RNA was diluted
five times for quantitative PCR amplification of various
cancer stem cell markers. Five microliters of comple-
mentary DNA products was amplified with SYBR Green
Quantitative PCR Master Mix (Applied Biosystems).
Table 1 provides the list and sequences of the mouse
and human specific primers used in the study. Reactions
were carried out in Applied Biosystems 7500 Real-Time
PCR System as described previously by Yu et al. [31].
The quantitation of the marker gene was normalized to
amplification of b-actin and subsequently expressed as
relative to untreated control.
Flow Cytometric Analyses for cancer stem cell markers
Parental (control) and chemo-resistant colon cancer
cells were subjected to direct immunofluorescence
staining followed by flow cytometric analyses. Briefly,
the cells were harvested and washed with PBS. Two
million cells were suspended in 90 μl of PBS contain-
ing 0.5% BSA for 10 minutes at room temperature fol-
lowed by the addition of 10 μl of PerCP cy5.5
fluorescent dye conjugated to CD44 and/or phyco-ery-
thrin conjugated CD-166 monoclonal antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) and incubated
for 30 minutes in the dark, at room temperature. The
Table 1 List of different PCR primers used in the study
Gene Specificity Direction Primer Sequence
CD 44 Mouse Forward ctccagacaaccaccaggat
CD 44 Mouse Reverse tgtggggtctcctcttcatc
CD 133 Mouse Forward tcaaagggacccagaaactg
CD 133 Mouse Reverse gccttgttcttggtgttggt
CD 166 Mouse Forward ctcgttgctggtgtcgtcta
CD 166 Mouse Reverse tccaatccgctcctctctta
ALDH 1a Mouse Forward gggctgacaagattcatggt
ALDH 1a Mouse Reverse ggaaaattccaggggatgat
Actin Mouse Forward agatctggcaccacaccttc
Actin Mouse Reverse ggggtgttgaaggtctcaaa
CD 44 Human Forward aaggtggagcaaacacaacc
CD 44 Human Reverse actgcaatgcaaactgcaag
CD 133 Human Forward accgactgagacccaacatc
CD 133 Human Reverse ggtgctgttcatgttctcca
CD 166 Human Forward tagcaggaatgcaactgtgg
CD 166 Human Reverse cgcagacatagtttccagca
ALDH 1a Human Forward gttgtcaaaccagcagagca
ALDH 1a Human Reverse ctgtaggcccataaccagga
Actin Human Forward cccagcacaatgaagatcaa
Actin Human Reverse acatctgctggaaggtggac
ALDH1a represents ALDH1.
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DiVa (BD, San Jose, CA).
Colonosphere Formation
To examine the effects of combination therapy on the
formation of colonospheres by chemo-resistant cells, the
ability of cell lines to form spheres in suspension was
evaluated as described by Liu et al [24], with minor
optimizations. Briefly, colonospheres were generated by
incubating CR HCT-116 cells at a concentration of 250
cells per 100 μL in serum-free stem cell medium (SCM)
containing DMEM/F12 (1:1) in 96-well ultra low-attach-
ment plates (Corning Inc, Lowell, MA). The stem cell
medium was supplemented with B27 (Life Technologies,
G a i t h e r s b u r g ,M D ) ,2 0n g / m lE G F( S i g m a ,S tL o u i s ,
MO), 10 ng/ml fibroblast growth factor (Sigma), and
antibiotic/antimycotic. After 24 h of cell seeding, dasati-
nib(1 μM) and curcumin(10 μM) were added to each
well. The colonospheres formed in 10 days were photo-
graphed for five to six microscopic fields under a 10×
objective. The colonospheres were further evaluated for
their size by measuring the widest area of the sphere.
Invasion assay
Invasion assay was performed as described by Nautiyal
et al [32] using a colorimetric assay from the Chemicon
International Inc. (Temecula, CA, USA). The kit utilizes
ECMatrix™, a reconstituted basement membrane matrix
of proteins. In brief, 5,000 CR HCT-116 cells were
seeded in the insert with or without dasatinib (1 μM)
and curcumin (10 μM), subsequently incubated at 37°C
for 72 h. The inserts contained an 8 μm pore size poly-
carbonate membrane covered with a thin layer of EMa-
trix™. The ECM layer occluded the membrane pores,
blocking the non-invasive cells from migrating through.
However, invading cells migrated through the ECM
layer and could be found attached to the bottom of
polycarbonate layer. At the end of the incubation, non-
invading cells were gently removed using a cotton-
tipped swab from interior of the inserts. The invasive
cells on the lower surface of inserts were stained with
500 μl of stain. For quantitation of invasive potential,
the stained cells were solubilized with 200 μlo f1 0 %
acetic acid and a consistent volume of dye/solute mix-
ture was read at 570 nm.
Statistical Analysis
Unless otherwise stated, data were expressed as mean ±
SD. Where applicable, the results were compared by
using the unpaired, two-tailed Student t-test, as imple-
mented by Excel 2007 (Microsoft Corp., Redmond,
WA). p-value smaller than 0.05 was considered statisti-
cally significant.
Results
The combination of dasatinib and curcumin is effective in
inhibiting cancer stem cell population in remnants of
spontaneous adenomas
Currently, CSCs are identified by specific surface epi-
topes. Colorectal CSCs cells were initially characterized
b yt h o s ee x p r e s s i n gC D 1 3 3a n ds u b s e q u e n t l yb yt h e
expression of other surface markers such as CD44,
CD166 and EpCAM/ESA (epithelial cell adhesion mole-
cule/epithelial-specific antigen) [35]. More recently,
aldehyde dehydrogenase 1 (ALDH1) which is a detoxify-
ing enzyme [36] has been identified as a specific marker
for normal and malignant human colonic stem cells
[37]. ALDH1-positive cells, which are sparse and limited
to the crypt bottom where stem cells reside, increase
with progression of normal epithelium to adenoma to
carcinoma [37]. We have recently reported that dasati-
nib in combination with curcumin is highly effective in
inhibiting cellular growth and transformation properties
in vitro and induces regression of over 90% of the spon-
taneous intestinal adenomas in APC
Min+/- mice [30].
This led to our interest in investigating the efficacy of
the combined therapy in targeting CSCs that are impli-
cated in the processes of chemo-resistance and recur-
rence of cancer. The initial experiment was carried out
to evaluate the effectiveness of the combination therapy
in inhibiting the growth of intestinal CSCs. For this, we
utilized adenoma remnants derived from our previous
study and examined the relative expression of various
C S Cs p e c i f i cm a r k e r s .F i g u r e1s h o w sam a r k e d8 0 - 9 0 %
reduction in the expression of the CSC markers in
response to the combination therapy, suggesting that
the combination of dasatinib and curcumin is highly
effective in reducing the cancer stem cell population in
adenomas, the precursor for adenocarcinoma. Although
dasatinib has met with limited success in solid tumors,
our observation that the expression of CSC markers was
greatly inhibited by dasatinib alone (Figure 1) provides a
rationale for utilizing this drug in combination with
more potent growth inhibitory agents like curcumin to
achieve a superior anti-tumor response.
Chemo-resistant colon cancer cells show increased
expression of stem cell markers
In an attempt to characterize the chemo-resistant (CR)
cells, the expression of CD133, CD44, CD166 and
ALDH1 was quantitated relative to the parent cell line
(Figure 2A). CR HCT-116 cells show higher expression
of each of these cancer stem cell markers than the par-
ental HCT-116 cells. CR colon cancer cells were also
investigated for dual staining for surface markers that
play significant role in adhesion, namely CD44 and
CD166. Both CR HCT-116 and CR HT-29 cells show
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kers concurrently (Figure 2B). Although the population
of dual staining cells was higher for HCT-116 cells, the
relative increase was much higher in CR HT-29 cells
(~6 time the parent cells) (Figure 2B). This suggests a
higher population of CSCs in chemo-resistant cells.
Therefore, we chose these cell lines as a model for test-
ing our hypothesis.
Combination therapy of dasatinib and curcumin is
effective in inhibiting chemo-resistant colon cancer cells
We have postulated that the combination therapy of
curcumin and dasatinib would be a superior therapeutic
strategy for chemo-resistant colorectal cancer. In order
to test our hypothesis we first evaluated the interactions
between dasatinib and curcumin in chemo-resistant
(CR) colon cancer cells. We performed synergy analysis
in CR HCT-116 and CR HT-29 cells, as described pre-
viously [30]. Dose response curves were generated for
both agents in CR colon cancer cells using Calcusyn
software (Biosoft, Ferguson, MO) (Figures 3A and 3B).
In each CR cell line the combination therapy caused a
greater growth inhibition than that achieved in response
to a single agent (Figures 3A and 3B). As observed
Figure 2 (A) Relative expression of various cancer stem cell markers in chemo-resistant (CR) HCT-116 cells as determined by RT-PCR;
(B) Sorting of anti-CD44 and anti-CD166 antibodies-tagged untreated (control) and CR HCT-116 and CR- HT-29 cells by flow
cytometry. Parental cells were maintained in DMEM, supplemented with 5% FBS and 1% antibiotic and antimycotic. The CR cells were
continuously exposed to 50 μM 5-FU and 1.25 μM oxaliplatin.
Figure 1 Relative expression of various cancer stem cell
markers in tumor remnants from APC
Min +/- mice treated with
dasatinib and/or curcumin as determined by RT-PCR. Tissue was
procured from our previous study where Female Min mice (5 weeks;
female C57BL/6J- APC
Min +/- ) were treated with dasatinib (10 mg/kg
body weight) and/or curcumin (250 mg/kg body weight). The
treatment was given for five consecutive days per week for 4 weeks.
At the end of respective treatments, the mice were euthanized and
tumor remnants were obtained as described previously [30]. RNA
isolated from the tissue was analyzed for expression of different
CSCs specific markers.
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be more effective in HT-29 (p53 mutant) cells than
HCT-116 cells.
The fraction of cells affected in response to each
treatment was thus utilized to perform synergy analysis
with Calcusyn software. The Combination Index (CI)
as formulated by the software, revealed values of less
than 1.0 indicating a synergistic interaction between
the two agents at most of the dose combinations tested
(Table 2). The results suggest that dasatinib and curcu-
min act synergistically to inhibit the growth of CR
colon cancer cells. Since dasatinib and curcumin
revealed synergistic interactions, the subsequent stu-
dies were performed with the combination of 1 μM
dasatinib and 10 μM curcumin. Similar to our recent
findings in parent cell lines [32], a higher synergy
(lower CI value) was observed for lower dose combina-
tions. Such synergistic interactions between various
drugs provides an opportunity to reduce the concen-
trations of the individual drug(s) and thereby, reducing
their associated toxicities.
Combining curcumin with dasatinb is an effective way to
reduce toxicity while retaining the therapeutic efficacy
Once the interaction between the two agents was found
to be synergistic, we next sought to determine the DRI
for dasatinib in CR colon cancer cells. Since combination
index (CI) for both cell lines show strong synergy
between dasatinib and curcumin, we performed DRI ana-
lysis for CR HCT-116 cells (Table 3). Our data show DRI
values for dasatinib in the range from 13 to 25 for CR
HCT-116 cells. The DRI data further demonstrated that
when used in combination with dietary agent curcumin,
dasatinib concentrations could be reduced significantly.
The combination of dasatinib and curcumin inhibit
colonosphere formation by chemo-resistant colon cancer
cells
We next investigated whether the combination therapy
would be effective in inhibiting the formation of
Figure 3 Effects of dasatinib and/or curcumin on the growth of (A) CR HCT-116 and (B) CR HT-29 colon cancer cells: Growth as
determined by MTT assay after 72-h incubation with incremental doses of dasatinib and/or curcumin. All CR cells were exposed to 50
μM 5-FU and 1.25 μM oxaliplatin with or without (control) dasatinib and/or curcumin. This treatment strategy was utilized in all subsequent
experiments. Dose response curves were generated for the drugs using Calcusyn 2.0 (Biosoft). All assays were performed in quadreplicates. A
fractional effect (Fa) of 1 represents complete toxicity for the drug(s), whereas Fa value of “0” indicates no effect.
Table 2 Synergy analysis for dasatinib and curcumin
combination therapy in chemo-resistant colon cancer
cells









0.25 2.5 0.42 0.16
0.5 5.0 0.43 0.28
1.0 10.0 0.61 0.46
2.0 20.0 0.72 0.76
4.0 40.0 0.95 0.89
Combination indices < 1.0 are increasingly supra-additive, whereas values >
1.0 are increasingly less than additive.
Table 3 Dose Reduction Index (DRI) analysis for dasatinb
in chemo-resistant HCT-116 colon cancer cells
Drug Reduction Index for Dasatinib
Fa DRI




DRI represents the order of magnitude (fold) of dose reduction obtained for
specific Fa in combination settings as compared to each drug alone.
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combination therapy was found to be highly effective in
inhibiting the sphere forming potential of both CR
HCT-116 and CR HT-29 cells (Figures 4A and 4B). At
the end of 10-day experimental period we observed that
while the control cells formed well-defined spheroids,
the CR cells treated with the combination therapy
showed significantly smaller spheres/spheroids (Figure
4C). The average sizes of colonospheres formed by the
untreated CR HCT-116 and CR HT-29 cells were ~111
and 177 μm respectively (Figure 4C). In contrast, the
average size of colonospheres formed in response to the
combination therapy was 40 and 38 μm, respectively
(Figure 4C). This suggests the current targeted therapy
is highly effective in inhibiting the stemness properties
of chemo-resistant colon cancer cells.
The combination of dasatinib and curcumin effectively
inhibit extracellular matrix invasion by chemo-resistant
colon cancer cells
Chemo-resistant cells are thought to be more aggressive
and have higher potential to invade through extracellu-
lar matrix leading to metastasis and spread of the pri-
mary malignancy than the parental cells. In view of this,
we investigated the effectiveness of the current combi-
nation therapy in inhibiting the invasion potential of CR
HCT-116 cells. Our results show that the chemo-resis-
tant HCT-116 cells have higher potential to invade as
compared to the corresponding parental cells and that
they are highly susceptible to the combination therapy
(Figure 5). This suggests that the combination therapy
of the two targeted agents may be effective in targeting
the chemo-resistant colon cancer.
The combination of dasatinib and curcumin is effective in
inhibiting cancer stem cell population in chemo-resistant
colon cancer cells
Since the combination therapy is effective in inducing
inhibition of growth, colonosphere formation and extra-
cellular invasion, we next sought to test if this regimen
would be effective in reducing the cancer stem cell
population. The expression of CSC markers CD133,
CD44, CD166 and ALDH1 was determined in the CR
HCT-116 cells treated with the combination therapy.
There was a 25-30% decrease in the expression of each
of the CSC marker (Figures 2A and 2B). Although the
CR cells displayed a higher expression of CSC markers
and a higher proportion of cells showed co-expression
of CD44 and CD166 (Figures 2A &2B), the combination
therapy greatly decreased thee x p r e s s i o no ft h e s ep r o -
teins (Figure 6). These findings suggest that the combi-
nation therapy is highly effective in reducing the CSC
Figure 4 Representative photograph showing formation of colonospheres by (A) CR HCT-116 and (B) CR HT-29 cells after incubating
with dasatinib(1 μM), and curcumin (10 μM). Average size of colonospheres formed by CR HCT-116 and CR HT-29 in response to the
combination therapy (C). The controls were incubated with FOLFOX (50 μM 5-FU + 1.25 μM oxaliplatin) containing medium only. *P < 0.01,
compared with the corresponding control.
Nautiyal et al. Journal of Molecular Signaling 2011, 6:7
http://www.jmolecularsignaling.com/content/6/1/7
Page 7 of 11sub-population in the chemo-resistant colon cancer and
may be utilized as a CSC targeted therapy for elimina-
tion of recurrence of colon cancer.
Discussion and Conclusion
Metastatic colorectal cancer remains incurable, indicat-
ing a poor prognosis and overall survival of about 2
years in surgically unresectable disease. FOLFOX is the
standard therapy for colorectal cancer with limited suc-
cess. Oxaliplatin, a platinum based chemotherapeutic
agent form platinum-DNA adducts and interferes with
DNA replication leading to cell death [38]. Development
of resistance to FOLFOX is a common phenomenon
leading to recurrence of the tumor. Src, a tyrosine
kinase, that regulates diverse cellular processes, has been
associated with various stages of cancer progression
with an inverse co-relation with patient survival [39].
Enhanced Src activity has been reported in > 70% colon
cancer, though the highest activity is demonstrated in
metastasis [40,41]. More recently, Src kinase has been
implicated in drug resistance [42] and is shown to be a
modulator of sensitivity to oxaliplatin [43]. Pre-clinical
evidence indicates that inhibition of Src renders the can-
cer cells susceptible to chemotherapies [44-46]. In light
of these findings, investigations are being carried out to
develop dasatinib, a highly potent Src inhibitor, as an
adjuvant therapy for treatment of cancer along with
inhibition of recurrence. However, administration of
multiple therapeutic agents is often associated with
additional toxicities which at times may be life threaten-
ing. Therefore, a combination with non-toxic dietary
agent like curcumin is expected to provide a superior
benefit. Curcumin, a phytochemical has been reported
to have anti-tumor effects in various solid tumors [27].
Curcumin has been shown to augment the effect of a
number of chemotherapeutic agents, including doxoru-
bicin and vincristine and has been shown to enhance
the cellular accumulation of these drugs leading to
increased sensitivity of the drug-resistant cancer cells
[47,48]. We have demonstrated that the combination of
curcumin and FOLFOX causes a marked inhibition of
growth of colon cancer cells [49]. More recently, we
reported that curcumin is highly effective in sensitizing
the FOLFOX surviving colon cancer cells [31]. The
chemo-resistant HCT-116 cells show increased expres-
sion of several biomarkers of CSCs, a greater ability to
form colonies and colonospheres, indicating an increase
in the CSCs population [31]. We demonstrated that cur-
cumin alone or in combination with FOLFOX markedly
decreases CSCs, as determined by decreased expression
of CSCs markers and colony as well as colonosphere
formation [31].
In the current investigation, we utilized FOLFOX
resistant cells derived from two colon cancer cell lines
with different mutational status; HCT-116 p53 wild type
(p53 wild type; K-ras mutant), HT-29 (K-ras wild type;
p53 mutant). We have recently reported synergistic
interaction between dasatinib and curcumin in parental
HCT-116 and HT-29 cells [32]. Herein, we report simi-
lar synergistic effects on the chemo-resistant derivatives
Figure 5 Effects of dasatinib and curcumin on extra cellular
invasion by CR HCT-116 colon cancer cells. CR HCT-116 cells
were allowed to invade in the presence or absence of dasatinib(1
μM), and curcumin (10 μM) for 3 days. The invading cells were
stained with crystal violet and solubilized for quantitation. The
controls represent the parental cells or CR HCT-116 cells that were
incubated with FOLFOX (50 μM 5-FU + 1.25 μM oxaliplatin)
containing medium only. *P < 0.01, compared with the
corresponding control.
Figure 6 Relative expression of various colon cancer stem cell
markers in chemo-resistant HCT-116 cells in response to the
exposure to dasatinib (1 μM), and curcumin (10 μM) for 3 days.
The controls represent the CR HCT-116 cells that were incubated
with FOLFOX (50 μM 5-FU + 1.25 μM oxaliplatin) containing
medium only. *P < 0.01, compared with the corresponding control.
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tion indices, like the parent cells, CR HT-29 cells also
show a higher susceptibility to the combination therapy
than CR HCT-116 cells. This can be explained on the
basis of recent findings of Kopetz et al. [43]. They
demonstrated that in HT-29 cells, the expression of Src
is greatly augmented in response to oxaliplatin, and thus
the inhibition of Src by dasatinib imparts greater sensi-
tivity to oxaliplatin. On the other hand, HCT-116 cells
that did not demonstrate an increase in Src expression
failed to show such synergy between the two agents.
Our current finding supports the contention that cancer
cells that are highly dependent on Src signaling will be
more susceptible to Src-targeted combination therapy.
Development of dasatinib as a therapeutic agent has
been hindered by the toxicities and associated adverse
effects. Our data, for the first time, demonstrate that by
using curcumin, dasatinib dose could be markedly
reduced as evidenced by the DRI calculations. This is
particularly significant in clinical situations where
reduced toxicity towards the host is much sought after.
These observations suggest that combining dietary
agents to conventional chemotherapeutics is greatly ben-
eficial in achieving better therapeutic effects.
Failure of current chemotherapies to eliminate CSCs is
thought to be a major hurdle in treating colon cancer.
C S C sp o s s e s st h ep o t e n t i a lt os e l f - r e n e wa sw e l la st o
differentiate into heterogenous population of cells within
the tumor. They are currently identified by the expres-
sion of specific surface and cytoplasmic markers. Poten-
tial markers for colon CSCs include CD133, CD44,
CD166 and ALDH1 [35]. Although the functional
importance of CD133 remains to be resolved [50], CD44
is a transmembrane glycoprotein that has a unique cell
adhesion function. CD44 plays a role in cancer cell
migration as well as matrix adhesion and is involved in
increased tumor growth [50,51]. CD166 is another adhe-
sion molecule whose functional role is unclear. How-
ever, the expression of CD166 is found to be increased
in primary adenocarcinomas and is associated with
shorter patient survival [52]. Another marker with func-
tional significance is aldehyde dehydrogenase 1
(ALDH1), which is a detoxifying metabolic enzyme,
found to be associated with stem cell population [53]. In
addition to being a potential cancer stem cell marker
[37], ALDH1 is proposed to be associated with chemo-
resistance of the subset of cells that show CD44 and
CD166 dual positivity [54]. We have observed that the
colon cancer cells that are continually exposed to FOL-
FOX lead to increased expression of CSC markers. Our
current data demonstrate increased expression of
CD133, CD44, CD166 and ALDH1 in chemo-resistant
colon cancer cells. Dalerba et al. have reported that
tumorigenicity is more specific and restricted to CSCs
that express both CD44 and CD166 [35]. Interestingly,
we have observed that CR HCT-116 as well as CR HT-
29 cells contain a higher proportion of cells that express
both CD44 and CD166 than the corresponding parental
cell lines. Taken together the results show that, the
chemo-resistant colon cancer cells are enriched in
CSCs. We also report that the remnants of spontaneous
adenomas from mice treated with dasatinib and/or cur-
cumin showed 80-90% decrease in the expression of the
CSC markers ALDH1, CD44, CD133, CD166.
Our current data demonstrate that the combination
therapy is highly effective in inhibiting the processes of
carcinogenesis as evidenced by decreased colonosphere
formation by the chemo-resistant cells that are highly
enriched in CSCs. CR HCT-116 cells also show a higher
invasive potential and greater susceptibility to the com-
bination therapy, suggesting that this treatment could be
an effective therapeutic strategy for targeting chemo-
resistant cancer cells. Furthermore, the combination
treatment is highly effective in eliminating the CSCs
population in the CR HCT-116 colon cancer cells. The
expression of CSC markers is significantly reduced in
response to the combination therapy. Considering the
fact that the combination therapy is highly effective in
inhibiting stem cell population in primary tumors as
well as chemo-resistant colon cancer cells, our current
observation suggests that the targeted combination regi-
men could be a superior strategy in eliminating CSCs
and may inhibit the re-emergence of colon cancer.
Additionally, incorporation of curcumin, a phytochem-
ical will enable us to achieve greater benefit with
reduced drug toxicities. This dietary agent which is well
tolerated, could be added to food and taken on a long-
term basis to either prevent primary tumor formation or
tumor recurrence [55].
List of abbreviations
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modified Eagle medium; EpCAM/ESA: epithelial cell adhesion/epithelial
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